Literature DB >> 25759096

Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment.

Edward M Kennedy1, Bryan R Cullen2.   

Abstract

CRISPR/Cas systems mediate bacterial adaptive immune responses that evolved to protect bacteria from bacteriophage and other horizontally transmitted genetic elements. Several CRISPR/Cas systems exist but the simplest variant, referred to as Type II, has a single effector DNA endonuclease, called Cas9, which is guided to its viral DNA target by two small RNAs, the crRNA and the tracrRNA. Initial efforts to adapt the CRISPR/Cas system for DNA editing in mammalian cells, which focused on the Cas9 protein from Streptococcus pyogenes (Spy), demonstrated that Spy Cas9 can be directed to DNA targets in mammalian cells by tracrRNA:crRNA fusion transcripts called single guide RNAs (sgRNA). Upon binding, Cas9 induces DNA cleavage leading to mutagenesis as a result of error prone non-homologous end joining (NHEJ). Recently, the Spy Cas9 system has been adapted for high throughput screening of genes in human cells for their relevance to a particular phenotype and, more generally, for the targeted inactivation of specific genes, in cell lines and in vivo in a number of model organisms. The latter aim seems likely to be greatly enhanced by the recent development of Cas9 proteins from bacterial species such as Neisseria meningitidis and Staphyloccus aureus that are small enough to be expressed using adeno-associated (AAV)-based vectors that can be readily prepared at very high titers. The evolving Cas9-based DNA editing systems therefore appear likely to not only impact virology by allowing researchers to screen for human genes that affect the replication of pathogenic human viruses of all types but also to derive clonal human cell lines that lack individual gene products that either facilitate or restrict viral replication. Moreover, high titer AAV-based vectors offer the possibility of directly targeting DNA viruses that infect discrete sites in the human body, such as herpes simplex virus and hepatitis B virus, with the hope that the entire population of viral DNA genomes might be destroyed. In conclusion, we believe that the continued rapid evolution of CRISPR/Cas technology will soon have a major, possibly revolutionary, impact on the field of virology.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiviral gene therapy; CRISPR/Cas; Gene editing; Sequence specific DNA cleavage

Mesh:

Substances:

Year:  2015        PMID: 25759096      PMCID: PMC4424069          DOI: 10.1016/j.virol.2015.02.024

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  60 in total

1.  Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.

Authors:  F Ann Ran; Patrick D Hsu; Chie-Yu Lin; Jonathan S Gootenberg; Silvana Konermann; Alexandro E Trevino; David A Scott; Azusa Inoue; Shogo Matoba; Yi Zhang; Feng Zhang
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

2.  Recombinant adeno-associated virus vector: use for transgene expression and anterograde tract tracing in the CNS.

Authors:  N L Chamberlin; B Du; S de Lacalle; C B Saper
Journal:  Brain Res       Date:  1998-05-18       Impact factor: 3.252

3.  Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells.

Authors:  Xuebing Wu; David A Scott; Andrea J Kriz; Anthony C Chiu; Patrick D Hsu; Daniel B Dadon; Albert W Cheng; Alexandro E Trevino; Silvana Konermann; Sidi Chen; Rudolf Jaenisch; Feng Zhang; Phillip A Sharp
Journal:  Nat Biotechnol       Date:  2014-04-20       Impact factor: 54.908

4.  High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells.

Authors:  Yuexin Zhou; Shiyou Zhu; Changzu Cai; Pengfei Yuan; Chunmei Li; Yanyi Huang; Wensheng Wei
Journal:  Nature       Date:  2014-04-09       Impact factor: 49.962

5.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

Review 6.  Targeting HIV latency: pharmacologic strategies toward eradication.

Authors:  Sifei Xing; Robert F Siliciano
Journal:  Drug Discov Today       Date:  2012-12-25       Impact factor: 7.851

Review 7.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering.

Authors:  Thomas Gaj; Charles A Gersbach; Carlos F Barbas
Journal:  Trends Biotechnol       Date:  2013-05-09       Impact factor: 19.536

8.  Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis.

Authors:  Zhonggang Hou; Yan Zhang; Nicholas E Propson; Sara E Howden; Li-Fang Chu; Erik J Sontheimer; James A Thomson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-12       Impact factor: 11.205

9.  Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo.

Authors:  Nathalia Holt; Jianbin Wang; Kenneth Kim; Geoffrey Friedman; Xingchao Wang; Vanessa Taupin; Gay M Crooks; Donald B Kohn; Philip D Gregory; Michael C Holmes; Paula M Cannon
Journal:  Nat Biotechnol       Date:  2010-07-02       Impact factor: 54.908

10.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo.

Authors:  Su-Ru Lin; Hung-Chih Yang; Yi-Ting Kuo; Chun-Jen Liu; Ta-Yu Yang; Ku-Chun Sung; You-Yu Lin; Hurng-Yi Wang; Chih-Chiang Wang; Yueh-Chi Shen; Fang-Yi Wu; Jia-Horng Kao; Ding-Shinn Chen; Pei-Jer Chen
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-19       Impact factor: 10.183

View more
  19 in total

1.  Stepping toward therapeutic CRISPR.

Authors:  Keith T Gagnon; David R Corey
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-07       Impact factor: 11.205

Review 2.  The CRISPR/Cas9 genome editing methodology as a weapon against human viruses.

Authors:  Martyn K White; Wenhui Hu; Kamel Khalili
Journal:  Discov Med       Date:  2015-04       Impact factor: 2.970

Review 3.  CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.

Authors:  Cheng Peng; Mengji Lu; Dongliang Yang
Journal:  Virol Sin       Date:  2015-10-22       Impact factor: 4.327

4.  CRISPR as a driving force: the Model T of biotechnology.

Authors:  Carlos Mariscal; Angel Petropanagos
Journal:  Monash Bioeth Rev       Date:  2016-06

5.  Applications of CRISPR technologies in research and beyond.

Authors:  Rodolphe Barrangou; Jennifer A Doudna
Journal:  Nat Biotechnol       Date:  2016-09-08       Impact factor: 54.908

Review 6.  The Conspicuity of CRISPR-Cpf1 System as a Significant Breakthrough in Genome Editing.

Authors:  Hadi Bayat; Mohammad Hossein Modarressi; Azam Rahimpour
Journal:  Curr Microbiol       Date:  2017-11-30       Impact factor: 2.188

7.  In vivo disruption of latent HSV by designer endonuclease therapy.

Authors:  Martine Aubert; Emily A Madden; Michelle Loprieno; Harshana S DeSilva Feelixge; Laurence Stensland; Meei-Li Huang; Alexander L Greninger; Pavitra Roychoudhury; Nixon Niyonzima; Thuy Nguyen; Amalia Magaret; Roman Galleto; Daniel Stone; Keith R Jerome
Journal:  JCI Insight       Date:  2016-09-08

Review 8.  A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System.

Authors:  Anna Bellizzi; Nicholas Ahye; Gauthami Jalagadugula; Hassen S Wollebo
Journal:  J Neuroimmune Pharmacol       Date:  2019-09-11       Impact factor: 4.147

Review 9.  Eradication Strategies for Chronic Hepatitis B Infection.

Authors:  Eleanor M P Wilson; Lydia Tang; Shyam Kottilil
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

Review 10.  Neurogenethics: An emerging discipline at the intersection of ethics, neuroscience, and genomics.

Authors:  Turhan Canli
Journal:  Appl Transl Genom       Date:  2015-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.